Article Versions Notes

Sgherza N, Battisti O, Curci P, Conticello C, Palmieri S, Derudas D, Germano C, Martino EA, Mele G, Pepa RD, et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals. 2025; 18(4):595. https://doi.org/10.3390/ph18040595

Sgherza, Nicola, Olga Battisti, Paola Curci, Concetta Conticello, Salvatore Palmieri, Daniele Derudas, Candida Germano, Enrica Antonia Martino, Giuseppe Mele, Roberta Della Pepa, and et al. 2025. "Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study" Pharmaceuticals 18, no. 4: 595. https://doi.org/10.3390/ph18040595

Sgherza, N., Battisti, O., Curci, P., Conticello, C., Palmieri, S., Derudas, D., Germano, C., Martino, E. A., Mele, G., Pepa, R. D., Fazio, F., Mele, A., Rossini, B., Palazzo, G., Roccotelli, D., Rasola, S., Petrucci, M. T., Pastore, D., Tarantini, G., ... Musto, P. (2025). Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals, 18(4), 595. https://doi.org/10.3390/ph18040595